Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04232657 · ClinicalTrials.gov registry record · Phase 2
Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
A Phase 2 study of Spinal Cord Injury (=3 Years) and Sublesional Bone Loss Secondary to SCI, sponsored by VA Office of Research and Development.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT04232657 is a Phase 2 study of Spinal Cord Injury (=3 Years) and Sublesional Bone Loss Secondary to SCI that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 36 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04232657, a Phase 2 study of Spinal Cord Injury (=3 Years) and Sublesional Bone Loss Secondary to SCI, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD). The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (\>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur \<1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Romosozumab
- DRUG Denosumab
Study Locations (2)
New Jersey
- Kessler Institute for Rehabilitation - West Orange
New York
- James J. Peters VA Medical Center, Bronx, NY - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04232657
The ClinicalTrials.gov registry entry for NCT04232657 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Spinal Cord Injury (=3 Years) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04232657 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT04232657 about?
NCT04232657 is a clinical study titled "Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI". Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in pe...
What is the current status of trial NCT04232657?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-03-01. Estimated completion is 2027-03-01.
What conditions does trial NCT04232657 study?
This clinical trial studies the following conditions: Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI.
What interventions are being tested in trial NCT04232657?
The interventions under investigation include: Placebo (DRUG), Romosozumab (DRUG), Denosumab (DRUG).
Who is sponsoring clinical trial NCT04232657?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04232657 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Spinal Cord Injury (=3 Years)
All registered trials for this condition
Sublesional Bone Loss Secondary to SCI
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.